The current estimated value of the breast biopsy market is US$ 2146.54 million in 2022. By 2032, the breast biopsy market is anticipated to grow at a 5.3% CAGR and reach a value of US$ 3,596.7 million.
Increasing sensitivity of women to mammary cancer, awareness initiatives and screenings of breast biopsy, and favorable reimbursements will help the global breast biopsy market to generate great revenue in the forecasted period.
A breast biopsy is done on a small piece of tissue removed from the breast to determine the absence or presence of cancer. Fine needle aspiration biopsy is one of the least invasive procedures available and is frequently used for breast biopsies as well as leaves no scars on the breast part. In this procedure, the ultrasound monitor directs the needle to the breast's target area.
A breast biopsy is suggested when a person has symptoms including a breast lump, breast dimpling, sore breast, nipple discharge, and peeling of the breast.
| Attributes | Details |
|---|---|
| Breast Biopsy Market CAGR | 32.5% |
| Breast Biopsy Market (2022) | US$ 5.93 Billion |
| Breast Biopsy Market (2032) | US$ 98.93 Billion |
The massive increase in women's risk of developing mammary cancer, along with screening programs and campaigns to raise awareness of the disease, is what is fueling the breast biopsy market's expansion.
Additionally, a broad and active research environment for breast biopsy has benefited from minimally invasive and the development of more accurate treatments for the early detection of breast cancer. The breast biopsy market is anticipated to grow due to the rising prevalence of breast cancer worldwide and the fact that these procedures are the least invasive.
The adoption of breast biopsy is also rising due to favorable reimbursement policies and various government initiatives, which are expected to drive the market.
Numerous negative outcomes, including significant blood loss, surgical infection, and extended recovery times, have been brought on by invasive procedures. However, the introduction of minimally invasive options like image-guided biopsy has produced reliable results. Breast biopsy market growth is anticipated to be driven by the rising acceptance of image-guided needle biopsy during the forecast period.
The surgical procedure used to conduct the biopsy tests carries risks, including the possibility of breast bruising, swelling, soreness, and infection at the site of the operation. The patient may choose to ignore some infection symptoms, such as warmth in the breasts, discharge from the site, redness in the site, or fever of more than 100°F, which could worsen the situation. These elements are impeding the market for breast biopsy expansion.
The North American region commands the largest market share for breast biopsy, followed by Europe. The breast biopsy market growth in the North American region is aided by the rising incidences of breast cancer and the rising demand for non-invasive treatments.
The European market for breast biopsy is anticipated to grow profitably during the anticipated period. The market for breast biopsy is expected to grow as a result of rising government spending on research studies into breast cancer and the adoption of technologically advanced treatments.
Due to their developing healthcare infrastructure, the regions of Latin America, the Middle East, and Africa are currently experiencing a period of rapid growth.
The huge rise in women's susceptibility to mammary cancer, along with screenings and awareness campaigns launched in their favor, are driving the growth of the breast biopsy market. Furthermore, minimally invasive and the development of more accurate treatments for the early detection of breast cancer have benefited to broad and active research environment for breast biopsy. The increasing incidence of breast cancer worldwide and the fact that they are the least invasive procedure will expand market expansion.
Additionally, favorable reimbursements policy and various initiatives taken by the government are increasing the adoption of breast biopsy, which is expected to propel the market in the upcoming year.
In the breast biopsy market, the North American region holds the highest market share followed by Europe. The increasing demand for non-invasive treatment and rising incidences of breast cancer will boost the market growth in the North American region.
The European market is expected to show lucrative growth in the forecasted period.
Government investment in breast cancer research studies is increasing as well as the adoption of technologically advanced treatment is anticipated to propel the breast biopsy market. Latin America, the Middle East, and Africa regions are at a blossoming stage and are expected to show sustainable growth in the near future, owing to the developing healthcare infrastructure.
Hologic, Inc., Becton, Dickinson, and Company, Danaher Corporation, Merit Medical Systems, Medtronic, IZI Medical Products, Argon Medical, STERYLAB S.r.l., Scion Medical Technologies LLC, QIAGEN, Biocept Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 5.3% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segment Covered | Product, Indication, End User, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Players | Hologic, Inc.; Becton; Dickinson and Company; Danaher Corporation; Merit Medical Systems; Medtronic; IZI Medical Products; Argon Medical; STERYLAB S.r.l.; Scion Medical Technologies LLC; QIAGEN; Biocept Inc.; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche Ltd. |
| Customization | Available Upon Request |
The global breast biopsy market is anticipated to register a CAGR of 3.3% during the forecast period.
The global breast biopsy market is projected to be about US$ 1046.3 Million by the end of the year 2032.
Explore Similar Insights
Breast Biopsy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
